This is a preview of subscription content, log in via an institution to check access.
Reference
Melendez-Torres G, et al. Clinical and cost-effectiveness of beta interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment 21: No. 52, Sep 2017. Available from: URL: https://dx.doi.org/10.3310/hta21520
Rights and permissions
About this article
Cite this article
DMTs not cost effective in RRMS in the UK. PharmacoEcon Outcomes News 787, 14 (2017). https://doi.org/10.1007/s40274-017-4342-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4342-8